Format

Send to

Choose Destination
Pancreas. 2002 Jan;24(1):8-14.

Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide.

Author information

1
Department of Laboratory Medicine, University of Padova, Italy.

Abstract

INTRODUCTION:

Pancreatic adenocarcinoma causes diabetes mellitus by releasing factors interfering with glucose metabolism.

AIMS:

We verified in isolated rat hepatocytes the molecular weight (MW) of the fraction from pancreatic cancer cell conditioned media (CM) that altered glucose metabolism and ascertained, using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) analysis, whether there is any common peptide in CM and in the sera of patients with pancreatic cancer.

METHODOLOGY:

Sera was obtained from patients with pancreatic cancer ( n = 14) and chronic pancreatitis ( n = 9) and healthy control subjects ( n = 10). Conditioned medium (CM) was obtained from the following cell lines: MIA PaCa 2, PSK-1, PANC-1, and CAPAN-1. Two fractions (MW of less than 30,000 Da and less than 10,000 Da) were obtained from patients' sera, from CM, and from non-CM (NCM) after two-step ultrafiltration. Rat hepatocytes were incubated with CM and NCM. The peptide profile of patients' sera, CM, and NCM were analyzed using MALDI-MS.

RESULTS:

In rat hepatocytes, glucose metabolism was impaired by CM from all the pancreatic cancer cell lines and by CM with an MW of less than 10,000 Da. Two peptides (m/z 2030 and 2726) were found in CM and patients' sera. Only the peptide at m/z 2030 was found to be associated with the presence of diabetes.

CONCLUSION:

A peptide at m/z 2030 may be a putative pancreatic cancer-associated diabetogenic factor.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center